Ferring Pharmaceuticals and Resolve

Program to Launch During RESOLVE’s National Infertility Awareness Week(R), April 25 – May 2 Across the Country

PARSIPPANY, N.J., April 27 /PRNewswire/ — Ferring Pharmaceuticals, which offers the broadest portfolio of fertility treatments in the U.S., has partnered with leading patient advocate organization, RESOLVE: The National Infertility Association, to launch the RESOLVE Nurse Liaison Program during National Infertility Awareness Week(R) (NIAW), April 25-May 2. The program was developed to create a network of nurses from every Society for Assisted Reproductive Technology (SART) member infertility center in the United States to serve as RESOLVE ambassadors in their medical practice. Since nurses play a crucial role in the patient care process, the program was designed to arm them with relevant information about treatment options and valuable educational materials for infertility patients.

Nurses who enroll in the RESOLVE Nurse Liaison Program will receive e-communication on a regular basis with up-to-date patient education materials and other available resources. In addition, RESOLVE will periodically ask for feedback from nurses on the current state of patient education in infertility and gaps that they see in patient’s knowledge.  As a member of this valuable program, nurses will be prominently featured on RESOLVE’s Web site and have the opportunity to contribute articles and speak at RESOLVE events.

"RESOLVE is proud to collaborate with Ferring Pharmaceuticals especially during National Infertility Awareness Week(R). Our goal is to spread information about infertility and its treatments to those fighting the disease of infertility," said Barbara Collura, RESOLVE’s executive director. "We are thrilled to be partnering with a leader in the field of infertility who can help RESOLVE provide vital information to the nurses who are on the front lines of the patient care journey."

"Ferring is pleased to be working with RESOLVE to give nurses the resources they need to enhance the patient care journey," said Olivier Delannoy, vice president, Infertility Business Unit at Ferring. "As a leader in providing patients with access to affordable and user-friendly treatment options, Ferring remains committed to supporting the reproductive community with the tools they need to help simplify the patient treatment process."

Nurses who are interested in becoming a member of the RESOLVE Nurse Liaison Program can visit www.resolve.org/nurseprogram. Upon receipt of the registration form, RESOLVE will send a program welcome packet that outlines the details of the program.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, manufactures and markets the largest family of fertility treatments in the U.S. The Company markets MENOPUR, BRAVELLE, REPRONEX(R) (menotropins for injection, USP), NOVAREL(R) (chorionic gonadotropin for injection, USP) and ENDOMETRIN(R) (progesterone) Vaginal Insert in the U.S. to infertility specialists and their patients. Ferring also offers the Q-CAP(TM), the first and only needle-free reconstitution device, for use with its fertility treatments.

Ferring’s line of orthopaedic and urology products includes EUFLEXXA(R) (1% sodium hyaluronic acid) and PROSED(R) DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate). Other products include: ACTHREL(R) (corticorelin ovine triflutate for injection), DESMOPRESSIN and DEGARELIX for injection.

The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/ gynecology, infertility and orthopaedics. For more information, call 888-337-7464 or visit www.ferringusa.com or www.ferringfertility.com.

About RESOLVE: The National Infertility Association

Founded in 1974, RESOLVE: The National Infertility Association, headquartered in McLean, VA, is the oldest and largest consumer-based, nonprofit group that provides education, advocacy and compassionate support for those struggling with infertility in the United States. Each year, RESOLVE and its nationwide network of affiliates handle more than 1.5 million contacts from people seeking information and help. For more information, visit the RESOLVE website at www.resolve.org.

SOURCE Ferring Pharmaceuticals